# To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults

> **NCT06578676** · PHASE1 · RECRUITING · sponsor: **Hyundai Pharm** · enrollment: 56 (estimated)

## Conditions studied

- Type 2 Diabetes
- Dyslipidemias

## Interventions

- **DRUG:** Empagliflozin 25 MG
- **DRUG:** Ezetimibe/Rosuvastatin 10/10mg
- **DRUG:** Empagliflozin 25 MG with Ezetimibe/Rosuvastatin 10/10mg

## Key facts

- **NCT ID:** NCT06578676
- **Lead sponsor:** Hyundai Pharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-20
- **Primary completion:** 2024-09-02
- **Final completion:** 2024-11-30
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2024-08-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06578676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06578676, "To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06578676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*